On World Hepatitis Day, the VA announced it had cured more than 100,000 veterans of hepatitis C virus infection (HCV). Now, the focus is detecting any liver disease still prevalent in patients who have been cured. Though the disease is cured, the liver disease remains and needs monitoring.
In 2017, the VA signed a $47 million contract to acquire FibroScans from Echosens. FibroScans shoots waves of sound through the liver to measure stiffness and is FDA approved. This allows patients to avoid painful biopsies. Though there is no FDA-approved treatment for non-alcoholic fatty liver disease or the sub-type, FibroScans have been a tremendous help.